Pharmaceutical Business review

Eli Lilly reports Q3 net loss

On a pro forma non-GAAP basis, the company recorded net income of $1.13 billion, or $1.04 per share in the third quarter of 2008, compared with third-quarter 2007 net income of $996.4 million, or $0.91 per share.

The company reported worldwide sales of $5.21 billion for the third quarter of 2008, a 14% increase when compared with the prior-year period.

For the first nine months of 2008, worldwide reported sales increased 13% and pro forma non-GAAP sales increased 12% to $15.17 billion, compared with sales for the same period in 2007. Reported net income and earnings per share were $1.56 billion and $1.42, respectively. On a pro forma non-GAAP basis, net income and earnings per share were $3.22 billion and $2.95, respectively.

John Lechleiter, president and CEO of Lilly, said: “In the third quarter, the underlying fundamentals of our business remained strong, highlighted by volume-driven sales growth and an expansion in gross margin. Our revised full-year earnings per share guidance reflect these strong fundamentals.”